Cargando…
Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system
OBJECTIVE: In 2017, the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) introduced a standardised process to appraise innovativeness of medicines. Innovative medicines are provided speeder market access and dedicated funds. Innovativeness criteria are: unmet therapeutic need, added the...
Autores principales: | Galeone, Carlotta, Bruzzi, Paolo, Jommi, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812109/ https://www.ncbi.nlm.nih.gov/pubmed/33441356 http://dx.doi.org/10.1136/bmjopen-2020-041259 |
Ejemplares similares
-
The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency
por: Jommi, Claudio, et al.
Publicado: (2023) -
Implementation of medicinal cannabis in Australia: innovation or upheaval? Perspectives from physicians as key informants, a qualitative analysis
por: Hallinan, Christine Mary, et al.
Publicado: (2021) -
NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium
por: Ford, John A, et al.
Publicado: (2012) -
Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021) -
A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
por: Kaltenthaler, Eva C, et al.
Publicado: (2012)